{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T15:55:30Z","timestamp":1769874930403,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["CP10.11"],"award-info":[{"award-number":["CP10.11"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["KJPB.08.07"],"award-info":[{"award-number":["KJPB.08.07"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Renin\u2013angiotensin\u2013aldosterone system (RAAS) blockade provides renoprotective effects in chronic kidney disease (CKD); yet progressive renal function loss remains common. Dietary sodium restriction potentiates the renoprotective effects of RAAS blockade. Vitamin D receptor activator (VDRA) treatment reduces proteinuria, inflammation and fibrosis, but whether these effects depend on sodium intake has not been studied. We hypothesized that the renoprotective effects of VDRA treatment, with or without RAAS blockade, are modulated by sodium intake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Six weeks after the induction of adriamycin nephrosis in Wistar rats, i.e. with established proteinuria, animals were treated with the VDRA paricalcitol, lisinopril, the combination, or vehicle; each treatment was given during either a high- (2% NaCl) or a low-sodium (0.05% NaCl) diet for 6 weeks. We assessed proteinuria, blood pressure, renal macrophage accumulation and renal expression of the pre-fibrotic marker alpha-smooth muscle actin (\u03b1-SMA) at the end of the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both paricalcitol and lisinopril individually, as well as in combination, reduced proteinuria and glomerular and interstitial inflammation during a low-sodium diet, but not during a high-sodium diet. All interventions also reduced focal glomerulosclerosis and interstitial expression of \u03b1-SMA during the low-sodium diet, while similar trends were observed during the high-sodium diet. The renoprotective effects of paricalcitol were not accompanied by blood pressure reduction. As proteinuria was already abolished by lisinopril during the low-sodium diet, the addition of paricalcitol had no further effect on proteinuria or downstream inflammatory or pre-fibrotic changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The renoprotective effects of the VDRA paricalcitol are blood pressure independent but do depend on dietary sodium status. The combination of RAAS blockade, dietary sodium restriction and VDRA may be a promising intervention to further retard renal function loss in CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfv304","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T19:59:08Z","timestamp":1440619148000},"page":"1293-1301","source":"Crossref","is-referenced-by-count":2,"title":["Sodium restriction potentiates the renoprotective effects of combined vitamin D receptor activation and angiotensin-converting enzyme inhibition in established proteinuric nephropathy"],"prefix":"10.1093","volume":"32","author":[{"given":"Katarina","family":"Mirkovic","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Roos S.","family":"Frenay","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"van den Born","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"van Goor","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerjan","family":"Navis","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H.","family":"de Borst","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the NIGRAM consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,8,25]]},"reference":[{"key":"2025102312492476700_GFV304C1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"2025102312492476700_GFV304C2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2025102312492476700_GFV304C3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(14)70030-0","article-title":"Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial","volume":"2","author":"Kwakernaak","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025102312492476700_GFV304C4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1681\/ASN.2011040430","article-title":"Sodium intake, ACE inhibition, and progression to ESRD","volume":"23","author":"Vegter","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025102312492476700_GFV304C5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ki.2012.74","article-title":"Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers","volume":"82","author":"Heerspink","year":"2012","journal-title":"Kidney Int"},{"key":"2025102312492476700_GFV304C6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrneph.2012.281","article-title":"Improving the efficacy of RAAS blockade in patients with chronic kidney disease","volume":"9","author":"Lambers Heerspink","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2025102312492476700_GFV304C7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/138945011793591572","article-title":"Vitamin D in chronic kidney disease: new potential for intervention","volume":"12","author":"Mirkovic","year":"2011","journal-title":"Curr Drug Targets"},{"key":"2025102312492476700_GFV304C8","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1681\/ASN.2013030203","article-title":"Active vitamin D treatment for reduction of residual proteinuria: a systematic review","volume":"24","author":"de Borst","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025102312492476700_GFV304C9","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"2025102312492476700_GFV304C10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/path.1405","article-title":"Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage","volume":"201","author":"Kramer","year":"2003","journal-title":"J Pathol"},{"key":"2025102312492476700_GFV304C11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/cs0900393","article-title":"Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis","volume":"90","author":"Wapstra","year":"1996","journal-title":"Clin Sci (Lond)"},{"key":"2025102312492476700_GFV304C12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/clinchem\/32.8.1551","article-title":"Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer","volume":"32","author":"Watanabe","year":"1986","journal-title":"Clin Chem"},{"key":"2025102312492476700_GFV304C13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ki.1989.190","article-title":"Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril","volume":"36","author":"Heeg","year":"1989","journal-title":"Kidney Int"},{"key":"2025102312492476700_GFV304C14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1161\/01.HYP.17.4.497","article-title":"Salt blocks the renal benefits of ramipril in diabetic hypertensive rats","volume":"17","author":"Fabris","year":"1991","journal-title":"Hypertension"},{"key":"2025102312492476700_GFV304C15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ki.1997.111","article-title":"A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function","volume":"51","author":"Apperloo","year":"1997","journal-title":"Kidney Int"},{"key":"2025102312492476700_GFV304C16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"2025102312492476700_GFV304C17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MNH.0000000000000073","article-title":"Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease","volume":"23","author":"Humalda","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025102312492476700_GFV304C18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000090222","article-title":"Sodium intake modifies the negative prognostic value of renal damage prior to treatment with ACE inhibitors on proteinuria induced by adriamycin","volume":"103","author":"Kramer","year":"2006","journal-title":"Nephron Physiol"},{"key":"2025102312492476700_GFV304C19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis","volume":"7","author":"Liu","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2025102312492476700_GFV304C20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2009.185","article-title":"Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism","volume":"5","author":"Doorenbos","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2025102312492476700_GFV304C21","doi-asserted-by":"crossref","first-page":"15896","DOI":"10.1073\/pnas.0803751105","article-title":"Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025102312492476700_GFV304C22","doi-asserted-by":"crossref","first-page":"F791","DOI":"10.1152\/ajprenal.00247.2009","article-title":"Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist","volume":"297","author":"Zhang","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025102312492476700_GFV304C23","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ki.2010.22","article-title":"Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes","volume":"77","author":"Deb","year":"2010","journal-title":"Kidney Int"},{"key":"2025102312492476700_GFV304C24","doi-asserted-by":"crossref","first-page":"d4366","DOI":"10.1136\/bmj.d4366","article-title":"Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial","volume":"343","author":"Slagman","year":"2011","journal-title":"Br Med J"},{"key":"2025102312492476700_GFV304C25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/1074248410377173","article-title":"Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren","volume":"15","author":"Weir","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025102312492476700_GFV304C26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1523-1755.2003.00708.x","article-title":"Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes","volume":"63","author":"Laverman","year":"2003","journal-title":"Kidney Int"},{"key":"2025102312492476700_GFV304C27","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfv033","article-title":"Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol","author":"Keyzer","year":"2016","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/8\/1293\/19381320\/gfv304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/8\/1293\/19381320\/gfv304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:50:12Z","timestamp":1761238212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/8\/1293\/3059403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,25]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,25]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfv304","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2015,8,25]]}}}